Blog
RSS FeedPosted by Michael Wonder on 15 May 2017
HTA programme response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries
15 May 2017 - Challenges commonly encountered in HTA of orphan medicinal products (OMPs) were identified in Advance-HTA. Since then, new ...
Posted by Michael Wonder on 11 May 2017
NICE publishes second appraisal consultation document for venetoclax
11 May 2017 - The first appraisal consultation in February 2017 recommended against the use of venetoclax on the NHS. ...
Posted by Michael Wonder on 10 May 2017
Cancer drug pricing: the truth and the rhetoric
9 May 2017 - Richard Torbett from the Association of the British Pharmaceutical Industry pens a letter to the Financial ...
Posted by Michael Wonder on 07 May 2017
Redistribution and redesign in health care: an ebbing tide in England versus growing concerns in the United States
4 May 2017 - Like many countries, the health care industries of England and the United States consume large amounts ...
Posted by Michael Wonder on 07 May 2017
New NICE criteria for drug access
1 May 2017 - An overhaul of NHS drug access in England by NICE and NHS England, which for the first ...
Posted by Michael Wonder on 06 May 2017
NICE rejects Orexigen’s weight-loss pill
5 May 2017 - The National Institute for Health and Care Excellence has published draft guidelines turning down Orexigen’s weight ...
Posted by Michael Wonder on 04 May 2017
Pfizer to give out breast cancer drug free while awaiting NHS decision
4 May 2017 - Pharmaceutical firm says it will offer palbociclib to patients while regulator rules on whether it should be ...
Posted by Michael Wonder on 03 May 2017
NICE recommends Janssen's first-of-its-kind Crohn's drug Stelara
3 May 2017 - Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the indication ...
Posted by Michael Wonder on 03 May 2017
Law finally passed to ban medicine price hiking by greedy drug firms
3 May 2017 - New legislation which is set to ban greedy drugs firms from extracting hundreds of millions of ...
Posted by Michael Wonder on 01 May 2017
NICE u-turn recommends some access to Takeda’s Adcetris
28 April 2017 - It is now looking likely that some patients with relapsed/refractory Hodgkin's lymphoma will be able to ...
Posted by Michael Wonder on 27 Apr 2017
NICE recommends Amgen's Blincyto (blinatumomab) for adults with relapsed or refractory Philadelphia chromosome negative B-precursor acute lymphoblastic leukaemia
27 April 2017 - FAD reinforces significant need for innovative treatment options for patients with relapsed or refractory acute lymphoblastic ...
Posted by Michael Wonder on 27 Apr 2017
New Government ‘must be more ambitious in securing a world-class NHS’, says UK pharmaceutical industry
27 April 2017 - The new Government must be more ambitious in securing a world-class NHS for patients and improve ...
Posted by Michael Wonder on 26 Apr 2017
NICE backs NHS use of Lilly’s Taltz for plaque psoriasis
26 April 2017 - US pharma major Eli Lilly says that Taltz (ixekizumab) has been recommended by the NICE for ...
Posted by Michael Wonder on 20 Apr 2017
Ipsen in talks with NICE over Cabometyx rejection
20 April 2017 - Ipsen says discussions with NICE are ongoing following a second rejection of Cabometyx for advanced renal ...
Posted by Michael Wonder on 19 Apr 2017
NICE nod for Novartis’ Cosentyx in psoriatic arthritis
19 April 2017 - NICE has published a positive Final Appraisal Determination which backs NHS use of Novartis’ Cosentyx (secukinumab) ...